These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 10583264)

  • 1. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics.
    Branford S; Hughes TP; Rudzki Z
    Br J Haematol; 1999 Dec; 107(3):587-99. PubMed ID: 10583264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimations of BCR-ABL/ABL transcripts by quantitative PCR in chronic myeloid leukaemia after allogeneic bone marrow transplantation and donor lymphocyte infusion.
    Otazú IB; Tavares Rde C; Hassan R; Zalcberg I; Tabak DG; Seuánez HN
    Leuk Res; 2002 Feb; 26(2):129-41. PubMed ID: 11755463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR.
    Emig M; Saussele S; Wittor H; Weisser A; Reiter A; Willer A; Berger U; Hehlmann R; Cross NC; Hochhaus A
    Leukemia; 1999 Nov; 13(11):1825-32. PubMed ID: 10557058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha.
    Reiter A; Marley SB; Hochhaus A; Sohal J; Raanani P; Hehlmann R; Gordon MY; Goldman JM; Cross NC
    Br J Haematol; 1998 Sep; 102(5):1271-8. PubMed ID: 9753056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
    Delage R; Soiffer RJ; Dear K; Ritz J
    Blood; 1991 Nov; 78(10):2759-67. PubMed ID: 1824268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
    Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interphase cytogenetics and competitive RT-PCR for residual disease monitoring in patients with chronic myeloid leukaemia during interferon-alpha therapy.
    Tchirkov A; Giollant M; Tavernier F; Briançon G; Tournilhac O; Kwiatkowski F; Philippe P; Choufi B; Deméocq F; Travade P; Malet P
    Br J Haematol; 1998 Jun; 101(3):552-7. PubMed ID: 9633901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction.
    Hochhaus A; Lin F; Reiter A; Skladny H; Mason PJ; van Rhee F; Shepherd PC; Allan NC; Hehlmann R; Goldman JM; Cross NC
    Blood; 1996 Feb; 87(4):1549-55. PubMed ID: 8608246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
    Guo JQ; Lin H; Kantarjian H; Talpaz M; Champlin R; Andreeff M; Glassman A; Arlinghaus RB
    Leukemia; 2002 Dec; 16(12):2447-53. PubMed ID: 12454751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
    Okamoto R; Harano H; Matsuzaki M; Motomura S; Maruta A; Kodama F; Mohri H; Okubo T
    Am J Clin Pathol; 1995 Nov; 104(5):510-6. PubMed ID: 7572810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative molecular methods to monitor the response of CML patients to interferon-alpha.
    Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman JM; Cross NC
    Bone Marrow Transplant; 1996 May; 17 Suppl 3():S41-4. PubMed ID: 8769700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.
    Cross NC; Feng L; Chase A; Bungey J; Hughes TP; Goldman JM
    Blood; 1993 Sep; 82(6):1929-36. PubMed ID: 8400243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage.
    Elmaagacli AH; Beelen DW; Opalka B; Seeber S; Schaefer UW
    Ann Hematol; 2000 Aug; 79(8):424-31. PubMed ID: 10985361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia.
    Roth MS; Antin JH; Ash R; Terry VH; Gotlieb M; Silver SM; Ginsburg D
    Blood; 1992 Jan; 79(1):276-82. PubMed ID: 1728316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.